Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
New England Journal of Medicine · 27.04.2023 · 388 (17) · 1572-1581
DOI: 10.1056/nejmoa2214171 ↗Kurz gefasst
Klinische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 27.04.2023. Verfasst von Inge M van der Sluis und 13 weiteren Autor:innen. Beteiligte Einrichtung: From the Princess Máxima Center for Pediatric Oncology (I.M.S., P.E.S.-H., R.P.), and the Dutch Childhood Oncology Group (I.M.S., R.P.) - both in Utr…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 225-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Australian Government, Børnecancerfonden, Princess Máxima Center Foundation.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: KMT2A-rearranged acute lymphoblastic leukemia (ALL) in infants is an aggressive disease with 3-year event-free survival below 40%. Most relapses occur during treatment, with two thirds occurring within 1 year and 90% within 2 years after diagnosis. Outcomes have not improved in recent decades despite intensification of chemotherapy. METHODS: We studied the safety and efficacy of blinatumomab, a bispecific T-cell engager molecule targeting CD19, in infants with KMT2A-rearranged ALL. Thirty patients younger than 1 year of age with newly diagnosed KMT2A-rearranged ALL were given the chemotherapy used in the Interfant-06 trial with the addition of one postinduction course of blinatumomab (15 μg per square meter of body-surface area per day; 28-day continuous infusion). The primary end point was clinically relevant toxic effects, defined as any toxic effect that was possibly or definitely attributable to blinatumomab and resulted in permanent discontinuation of blinatumomab or death. Minimal residual disease (MRD) was measured by polymerase chain reaction. Data on adverse events were collected. Outcome data were compared with historical control data from the Interfant-06 trial. RESULTS: The median follow-up was 26.3 months (range, 3.9 to 48.2). All 30 patients received the full course of blinatumomab. No toxic effects meeting the definition of the primary end point occurred. Ten serious adverse events were reported (fever [4 events], infection [4], hypertension [1], and vomiting [1]). The toxic-effects profile was consistent with that reported in older patients. A total of 28 patients (93%) either were MRD-negative (16 patients) or had low levels of MRD (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Princess Máxima Center for Pediatric Oncology (I.M.S., P.E.S.-H., R.P.), and the Dutch Childhood Oncology Group (I.M.S., R.P.) - both in Utrecht, the Netherlands; Tettamanti Center (P.L.) and Biostatistics and…
ORCID-Profile: Inge M van der Sluis, Rishi S Kotecha, Andishe Attarbaschi, Franco Locatelli
Förderung
- Australian Government
- Børnecancerfonden
- Princess Máxima Center Foundation
- Amgen
- Australian Government’s Medical Research Future Fund
- Erasmus MC Sophia Foundation
- Federation Enfants et Santé and the Société Française de lute contre les cancers et les leucémies de l’enfant et de l’adolescent
Zitieren
APA
van der Sluis, I. M., de Lorenzo, P., Kotecha, R. S., Attarbaschi, A., Escherich, G., Nysom, K., Stary, J., Ferster, A., Brethon, B., Locatelli, F., Schrappe, M., Scholte-van Houtem, P. E., Valsecchi, M. G., & Pieters, R. (2023). Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. New England Journal of Medicine, 388(17), 1572-1581. https://doi.org/10.1056/nejmoa2214171
Vancouver
van der Sluis IM, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. New England Journal of Medicine. 2023;388(17):1572-1581. doi:10.1056/nejmoa2214171
BibTeX
@article{vanderSluis2023,
author = {van der Sluis, Inge M and de Lorenzo, Paola and Kotecha, Rishi S and Attarbaschi, Andishe and Escherich, Gabriele and Nysom, Karsten and Stary, Jan and Ferster, Alina and Brethon, Benoit and Locatelli, Franco and Schrappe, Martin and Scholte-van Houtem, Peggy E and Valsecchi, Maria G and Pieters, Rob},
title = {Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {17},
pages = {1572--1581},
doi = {10.1056/nejmoa2214171}
}
EUVIMED